Warning! GuruFocus detected
2 Severe warning signs
with HIK.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Hikma Pharmaceuticals PLC
ISIN : GB00B0LCW083
Share Class Description:
LSE:HIK: Ordinary SharesCompare
Compare
Traded in other countries / regions
HIK.UKHKMPF.USAH5P.GermanyHIK.United Arab Emirates Index Membership
STOXX Europe 600FTSE 100iShares MSCI ACWI Ex US Index FundSTOXX Europe 600FTSE 100FTSE 250 IPO Date
2005-11-04Description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.16 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | 1.8 | |||||
| Interest Coverage | 8.16 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.78 | |||||
| Beneish M-Score | -2.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.3 | |||||
| 3-Year EBITDA Growth Rate | 2.3 | |||||
| 3-Year EPS without NRI Growth Rate | 6.4 | |||||
| 3-Year FCF Growth Rate | -4.1 | |||||
| 3-Year Book Growth Rate | 1.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 6.01 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 3.32 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.9 | |||||
| 9-Day RSI | 55.58 | |||||
| 14-Day RSI | 48.44 | |||||
| 3-1 Month Momentum % | -6.76 | |||||
| 6-1 Month Momentum % | 1.9 | |||||
| 12-1 Month Momentum % | 9.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.14 | |||||
| Quick Ratio | 0.65 | |||||
| Cash Ratio | 0.11 | |||||
| Days Inventory | 200.01 | |||||
| Days Sales Outstanding | 102.07 | |||||
| Days Payable | 85.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.2 | |||||
| Dividend Payout Ratio | 0.36 | |||||
| 3-Year Dividend Growth Rate | 17 | |||||
| Forward Dividend Yield % | 3.2 | |||||
| 5-Year Yield-on-Cost % | 6 | |||||
| 3-Year Average Share Buyback Ratio | 1.6 | |||||
| Shareholder Yield % | 3.29 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.24 | |||||
| Operating Margin % | 19.55 | |||||
| Net Margin % | 11.47 | |||||
| FCF Margin % | 10.54 | |||||
| ROE % | 15.83 | |||||
| ROA % | 7.34 | |||||
| ROIC % | 11.67 | |||||
| 3-Year ROIIC % | 4.66 | |||||
| ROC (Joel Greenblatt) % | 26.92 | |||||
| ROCE % | 15.94 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.14 | |||||
| Forward PE Ratio | 11.18 | |||||
| PE Ratio without NRI | 11.03 | |||||
| Shiller PE Ratio | 25.15 | |||||
| Price-to-Owner-Earnings | 19 | |||||
| PEG Ratio | 6.49 | |||||
| PS Ratio | 1.75 | |||||
| PB Ratio | 2.32 | |||||
| Price-to-Tangible-Book | 4.59 | |||||
| Price-to-Free-Cash-Flow | 16.53 | |||||
| Price-to-Operating-Cash-Flow | 9.65 | |||||
| EV-to-EBIT | 12.03 | |||||
| EV-to-Forward-EBIT | 11.07 | |||||
| EV-to-EBITDA | 8.76 | |||||
| EV-to-Forward-EBITDA | 7.65 | |||||
| EV-to-Revenue | 2.03 | |||||
| EV-to-Forward-Revenue | 1.99 | |||||
| EV-to-FCF | 19.21 | |||||
| Price-to-GF-Value | 0.88 | |||||
| Price-to-Projected-FCF | 0.93 | |||||
| Price-to-DCF (Earnings Based) | 0.86 | |||||
| Price-to-DCF (FCF Based) | 1.21 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Graham-Number | 1.49 | |||||
| Earnings Yield (Greenblatt) % | 8.31 | |||||
| FCF Yield % | 6.19 | |||||
| Forward Rate of Return (Yacktman) % | 7.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hikma Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 2,465.612 | ||
| EPS (TTM) (£) | 1.269 | ||
| Beta | 1.16 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.07 | ||
| Volatility % | 20.94 | ||
| 14-Day RSI | 48.44 | ||
| 14-Day ATR (£) | 0.448538 | ||
| 20-Day SMA (£) | 18.868 | ||
| 12-1 Month Momentum % | 9.54 | ||
| 52-Week Range (£) | 17.5 - 23.6 | ||
| Shares Outstanding (Mil) | 220.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hikma Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hikma Pharmaceuticals PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hikma Pharmaceuticals PLC Frequently Asked Questions
What is Hikma Pharmaceuticals PLC(LSE:HIK)'s stock price today?
The current price of LSE:HIK is £18.99. The 52 week high of LSE:HIK is £23.60 and 52 week low is £17.50.
When is next earnings date of Hikma Pharmaceuticals PLC(LSE:HIK)?
The next earnings date of Hikma Pharmaceuticals PLC(LSE:HIK) is 2025-08-07.
Does Hikma Pharmaceuticals PLC(LSE:HIK) pay dividends? If so, how much?
The Dividend Yield %  of Hikma Pharmaceuticals PLC(LSE:HIK) is 3.2% (As of Today), Highest Dividend Payout Ratio of Hikma Pharmaceuticals PLC(LSE:HIK) was 0.38. The lowest was 0.18. And the median was 0.28. The  Forward Dividend Yield % of Hikma Pharmaceuticals PLC(LSE:HIK) is 3.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers